Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
The treatment of severe dystonia in children and adults.
Marsden CD, Marion MH, Quinn N. Marsden CD, et al. J Neurol Neurosurg Psychiatry. 1984 Nov;47(11):1166-73. doi: 10.1136/jnnp.47.11.1166. J Neurol Neurosurg Psychiatry. 1984. PMID: 6502174 Free PMC article.
Twenty-three children (aged less than 18 years) and 17 adults with severe widespread dystonia were treated with high doses of benzhexol (up to 130 mg daily introduced slowly over many weeks). ...When benzhexol treatment alone fails in adults with severe disabling ax …
Twenty-three children (aged less than 18 years) and 17 adults with severe widespread dystonia were treated with high doses of …
Progabide in the treatment of hyperkinetic extrapyramidal movement disorders.
Mondrup K, Dupont E, Braendgaard H. Mondrup K, et al. Acta Neurol Scand. 1985 Sep;72(3):341-3. doi: 10.1111/j.1600-0404.1985.tb00881.x. Acta Neurol Scand. 1985. PMID: 3864333
The ability of the selective GABA-receptor agonist, progabide, to suppress abnormal involuntary movements was evaluated in a preliminary open pilot study. 17 patients, 10 males and 7 females, aged 10-78 years, with hyperkinetic movement disorders were included in the study …
The ability of the selective GABA-receptor agonist, progabide, to suppress abnormal involuntary movements was evaluated in a preliminary ope …